FDA accepts biologics license application for imlifidase in kidney transplantation – Hansa Biopharma
Hansa Biopharma AB announced that its Biologics License Application (BLA) for imlifidase has been accepted by the FDA. The FDA’s filing review was completed on day 60 which… read more.
